# 🏆 ULTIMATE MOAT: END-TO-END AGENTIC ONCOLOGY ORCHESTRATION

**Purpose:** Blueprint for the complete CrisPRO.ai product workflow - from data upload to continuous care orchestration with agentic intelligence.

**Last Updated:** December 3, 2025  
**Status:** MASTER BLUEPRINT | Priority: CRITICAL

---

## 🎯 THE VISION

> **"Upload once. Track forever. Never miss a signal."**

A patient's genomic data enters the system once. From that moment, an agentic swarm takes over - calculating biomarkers, predicting resistance, matching trials, generating nutrition plans, and continuously monitoring for signals that require action. The oncologist receives actionable intelligence, not raw data.

---

## 📊 THE COMPLETE MOAT STACK

### Layer 1: Validated Biomarker Capabilities

| Capability | Validation | Status | What It Does |
|------------|------------|--------|--------------|
| **TMB Calculation** | r=0.933, 95.4% accuracy | ✅ Production | Calculate TMB from mutations |
| **TMB-H Classification** | Validated against TCGA | ✅ Production | Classify IO eligibility (≥10 mut/Mb) |
| **MAPK Resistance** | RR=1.97, p<0.05 | ✅ Production | Predict platinum resistance |
| **MSI Detection** | Logic ready | ⏳ Need data | Detect dMMR/MSI-H |
| **HRD Inference** | MBD4 + BRCA logic | ✅ Production | Infer PARP eligibility |

### Layer 2: Clinical Intelligence Capabilities

| Capability | Source | Status | What It Does |
|------------|--------|--------|--------------|
| **Toxicity-Nutrition** | Drug MoA + Food DB | ✅ Production | Protective nutrition per drug |
| **Trial Matching** | ClinicalTrials.gov API | ✅ Production | Match patient to trials |
| **SOC Recommendations** | NCCN Guidelines | ✅ Production | Standard of care with confidence |
| **Drug Efficacy (S/P/E)** | Evo2 + Pathway + Evidence | ✅ Production | Per-drug efficacy ranking |

### Layer 3: Agentic Monitoring Capabilities

| Capability | Trigger | Status | What It Does |
|------------|---------|--------|--------------|
| **CA-125 Kinetics** | >25% rise | 🔄 Building | Early resistance detection |
| **ctDNA Monitoring** | Variant reappearance | 🔄 Building | MRD detection |
| **Treatment Response** | RECIST criteria | 🔄 Building | Response classification |
| **Adverse Events** | CTCAE grading | 🔄 Building | Toxicity monitoring |

---

## 🔄 THE MASTER WORKFLOW

### Phase 0: Data Upload & Ingestion

```
┌─────────────────────────────────────────────────────────────────────────┐
│                         DATA UPLOAD PORTAL                               │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                          │
│  📤 UPLOAD PATIENT DATA                                                  │
│  ┌─────────────────────────────────────────────────────────────────┐    │
│  │  Drag & drop or click to upload:                                │    │
│  │  • NGS Report (VCF, MAF, PDF, JSON)                            │    │
│  │  • Clinical Notes (PDF, TXT)                                    │    │
│  │  • Lab Results (PDF, CSV)                                       │    │
│  │  • Imaging Reports (PDF)                                        │    │
│  │  • Pathology Report (PDF)                                       │    │
│  └─────────────────────────────────────────────────────────────────┘    │
│                                                                          │
│  📋 OR ENTER MANUALLY:                                                   │
│  • Gene/Variant: [BRAF V600E        ]                                   │
│  • Disease:      [Multiple Myeloma  ▼]                                  │
│  • Stage:        [III              ▼]                                   │
│                                                                          │
│  [🚀 INITIATE FULL ANALYSIS]                                            │
│                                                                          │
└─────────────────────────────────────────────────────────────────────────┘
```

### Phase 1: Agentic Data Extraction

**Trigger:** File upload detected

```
┌──────────────────────────────────────────────────────────────────┐
│  🤖 DATA EXTRACTION AGENT                                        │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Input: Raw file (NGS PDF, VCF, etc.)                           │
│                                                                  │
│  Actions:                                                        │
│  1. Detect file type (PDF, VCF, MAF, JSON)                      │
│  2. Parse mutations (gene, variant, VAF, coverage)              │
│  3. Extract clinical data (stage, histology, biomarkers)        │
│  4. Extract demographics (age, sex, ECOG)                       │
│  5. Validate data quality (missing fields, coverage thresholds) │
│  6. Flag ambiguities for human review                           │
│                                                                  │
│  Output: Structured PatientProfile object                        │
│                                                                  │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  PatientProfile:                                           │ │
│  │    patient_id: "AYE-001"                                   │ │
│  │    disease: "ovarian_cancer"                               │ │
│  │    histology: "high_grade_serous"                          │ │
│  │    stage: "IVB"                                            │ │
│  │    mutations: [                                            │ │
│  │      { gene: "MBD4", variant: "c.1239delA", zygosity: "hom"}│ │
│  │      { gene: "TP53", variant: "R175H", source: "IHC" }     │ │
│  │    ]                                                       │ │
│  │    germline_panel: { brca1: "negative", brca2: "negative" }│ │
│  │    data_quality_flags: ["hrd_pending", "ca125_missing"]    │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

### Phase 2: Biomarker Calculation Pipeline

**Trigger:** PatientProfile extracted

```
┌──────────────────────────────────────────────────────────────────┐
│  🧬 BIOMARKER CALCULATION AGENT                                  │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Input: PatientProfile.mutations[]                               │
│                                                                  │
│  Parallel Calculations:                                          │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  TMB CALCULATION                                           │ │
│  │  • Count nonsynonymous mutations                           │ │
│  │  • Divide by exome size (38 Mb)                           │ │
│  │  • Result: 3.2 mut/Mb → TMB-L                             │ │
│  │  • Validation: r=0.933 vs TCGA                            │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  MSI DETECTION                                             │ │
│  │  • Check dMMR genes: MLH1, MSH2, MSH6, PMS2, EPCAM        │ │
│  │  • Result: No dMMR mutations → MSS                        │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  HRD INFERENCE                                             │ │
│  │  • Check HRR genes: BRCA1/2, ATM, ATR, PALB2, RAD51       │ │
│  │  • Check BER genes: MBD4 ← FOUND!                         │ │
│  │  • MBD4 homozygous loss → BER deficiency → HRD-like       │ │
│  │  • Result: HRD-INFERRED (awaiting Myriad score)           │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  IO ELIGIBILITY                                            │ │
│  │  • TMB-H (≥10)? NO                                        │ │
│  │  • MSI-H? NO                                              │ │
│  │  • Result: IO NOT ELIGIBLE (by current biomarkers)        │ │
│  │  • Note: MBD4 loss may cause elevated TMB - pending NGS   │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
│  Output: BiomarkerProfile                                        │
│  {                                                               │
│    tmb: 3.2,                                                    │
│    tmb_classification: "TMB-L",                                 │
│    msi_status: "MSS",                                           │
│    hrd_status: "HRD-INFERRED",                                  │
│    hrd_mechanism: "MBD4_BER_DEFICIENCY",                        │
│    io_eligible: false,                                          │
│    parp_eligible: true,                                         │
│    validation_provenance: {                                      │
│      tmb: "TCGA Pan-Immune r=0.933"                             │
│    }                                                            │
│  }                                                               │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

### Phase 3: Resistance Prediction

**Trigger:** BiomarkerProfile calculated

```
┌──────────────────────────────────────────────────────────────────┐
│  ⚔️ RESISTANCE PREDICTION AGENT                                  │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Input: PatientProfile.mutations[], current_treatment            │
│                                                                  │
│  Pathway Analysis:                                               │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  MAPK PATHWAY CHECK (Validated RR=1.97)                    │ │
│  │  • KRAS: Not detected                                      │ │
│  │  • NRAS: Not detected                                      │ │
│  │  • BRAF: Not detected                                      │ │
│  │  • NF1: Not detected                                       │ │
│  │  • MEK1/2: Not detected                                    │ │
│  │  → MAPK pathway: WILD-TYPE                                 │ │
│  │  → Platinum resistance risk: BASELINE (14.5%)              │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  DDR PATHWAY CHECK                                         │ │
│  │  • MBD4: HOMOZYGOUS LOSS ⭐                                │ │
│  │  • TP53: MUTANT (IHC)                                      │ │
│  │  → DDR pathway: SEVERELY COMPROMISED                       │ │
│  │  → Platinum sensitivity: HIGH (BER deficiency)             │ │
│  │  → PARP sensitivity: VERY HIGH (synthetic lethality)       │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
│  Output: ResistancePrediction                                    │
│  {                                                               │
│    platinum_sensitivity: "HIGH",                                 │
│    platinum_resistance_risk: 0.145,  // Baseline                │
│    parp_sensitivity: "VERY_HIGH",                               │
│    parp_resistance_risk: 0.10,                                  │
│    mechanism: "MBD4_TP53_SYNTHETIC_LETHALITY",                  │
│    signals_detected: 0,  // No MAPK mutations                   │
│    monitoring_priority: ["MAPK_mutations", "ABCB1_expression"], │
│    validation: "TCGA-OV 469 patients, MAPK RR=1.97"             │
│  }                                                               │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

### Phase 4: Drug Efficacy Ranking (S/P/E)

**Trigger:** ResistancePrediction complete

```
┌──────────────────────────────────────────────────────────────────┐
│  💊 DRUG EFFICACY AGENT (S/P/E Framework)                        │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Input: PatientProfile, BiomarkerProfile, ResistancePrediction   │
│                                                                  │
│  S/P/E Calculation per Drug:                                     │
│  Formula: efficacy = 0.3*S + 0.4*P + 0.3*E + clinvar_prior      │
│                                                                  │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  DRUG: OLAPARIB (PARP Inhibitor)                          │ │
│  │  S (Sequence): Evo2 delta for MBD4 c.1239delA = -2.3      │ │
│  │  P (Pathway): DDR pathway burden = 0.92                    │ │
│  │  E (Evidence): 127 papers, 3 RCTs (SOLO1, PRIMA, PAOLA)   │ │
│  │  ClinVar: Pathogenic (MBD4 frameshift)                     │ │
│  │  → Efficacy Score: 0.94 ⭐ HIGHEST                         │ │
│  │  → Confidence: HIGH (multiple RCTs)                        │ │
│  │  → Tier: I (On-label for HRD+)                            │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  DRUG: CARBOPLATIN (Platinum)                              │ │
│  │  S (Sequence): Evo2 delta for TP53 R175H = -1.8           │ │
│  │  P (Pathway): DDR pathway burden = 0.92                    │ │
│  │  E (Evidence): Standard of care, 1000+ papers             │ │
│  │  → Efficacy Score: 0.88                                    │ │
│  │  → Confidence: VERY HIGH (SOC)                            │ │
│  │  → Tier: I (First-line SOC)                               │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  DRUG: PEMBROLIZUMAB (Checkpoint Inhibitor)                │ │
│  │  S (Sequence): N/A (IO mechanism)                          │ │
│  │  P (Pathway): IO pathway = 0.0 (TMB-L, MSS)               │ │
│  │  E (Evidence): 45 papers, but not for TMB-L/MSS           │ │
│  │  → Efficacy Score: 0.32                                    │ │
│  │  → Confidence: LOW (no IO biomarker)                       │ │
│  │  → Tier: III (Research only)                              │ │
│  │  ⚠️ NOTE: Pending TMB from NGS - may change               │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
│  Output: DrugRanking[]                                           │
│  [                                                               │
│    { drug: "Olaparib", efficacy: 0.94, tier: "I", conf: "HIGH" }│
│    { drug: "Carboplatin", efficacy: 0.88, tier: "I", conf: "VH" }│
│    { drug: "Niraparib", efficacy: 0.91, tier: "I", conf: "HIGH" }│
│    { drug: "Bevacizumab", efficacy: 0.72, tier: "II", conf: "M" }│
│    { drug: "Pembrolizumab", efficacy: 0.32, tier: "III", conf: "L"}│
│  ]                                                               │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

### Phase 5: Trial Matching

**Trigger:** DrugRanking complete

```
┌──────────────────────────────────────────────────────────────────┐
│  🔬 TRIAL MATCHING AGENT                                         │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Input: PatientProfile, BiomarkerProfile, 7D MechanismVector     │
│                                                                  │
│  Mechanism Vector (7D):                                          │
│  [DDR=0.92, MAPK=0.0, PI3K=0.15, VEGF=0.10, HER2=0.0, IO=0.0, Efflux=0.0]│
│                                                                  │
│  Query Generation:                                               │
│  • "MBD4 mutation ovarian cancer clinical trial"                │
│  • "BER deficiency PARP inhibitor trial"                        │ │
│  • "DNA repair deficiency basket trial"                         │
│  • "TP53 mutant ovarian cancer trial"                           │
│  • "HRD positive maintenance therapy trial"                     │
│                                                                  │
│  Mechanism Fit Ranking:                                          │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  NCT05678901: PARP + ATR Inhibitor in DDR-Deficient OC    │ │
│  │  • Trial MoA Vector: [DDR=0.95, MAPK=0.0, ...]            │ │
│  │  • Mechanism Fit: 0.94 ⭐                                  │ │
│  │  • Eligibility: 0.92                                       │ │
│  │  • Combined Score: 0.93                                    │ │
│  │  • Why Matched: DDR pathway alignment (0.95 vs 0.92)      │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  NCT04729387: Olaparib + Cediranib vs Olaparib            │ │
│  │  • Trial MoA Vector: [DDR=0.90, VEGF=0.70, ...]           │ │
│  │  • Mechanism Fit: 0.88                                     │ │
│  │  • Eligibility: 0.95                                       │ │
│  │  • Combined Score: 0.90                                    │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
│  Output: TrialMatches[]                                          │
│  [                                                               │
│    { nct_id: "NCT05678901", mechanism_fit: 0.94, ... },         │
│    { nct_id: "NCT04729387", mechanism_fit: 0.88, ... },         │
│    { nct_id: "NCT05238922", mechanism_fit: 0.85, ... },         │
│  ]                                                               │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

### Phase 6: Toxicity-Aware Nutrition

**Trigger:** Treatment plan finalized

```
┌──────────────────────────────────────────────────────────────────┐
│  🥗 TOXICITY-NUTRITION AGENT                                     │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Input: TreatmentPlan.drugs[], PatientProfile.germline           │
│                                                                  │
│  Analysis per Drug:                                              │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  DRUG: CARBOPLATIN                                         │ │
│  │  MoA: DNA crosslinks → DDR pathway stress                  │ │
│  │  Germline: MBD4 homozygous (BER deficiency)               │ │
│  │  Combined Stress: EXTREME (no BER backup)                  │ │
│  │                                                            │ │
│  │  Recommendations:                                          │ │
│  │  ✅ NAC 600mg: Post-infusion (glutathione precursor)      │ │
│  │  ✅ Vitamin D 2000 IU: Daily (DNA repair support)         │ │
│  │  ✅ Omega-3 2g: Daily (anti-inflammatory)                 │ │
│  │  ✅ Zinc 15mg: Daily (enzyme cofactor)                    │ │
│  │  ⚠️ AVOID during infusion: High-dose antioxidants        │ │
│  │  ⚠️ AVOID: Grapefruit (CYP3A4 interaction)               │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  DRUG: OLAPARIB (Maintenance)                              │ │
│  │  MoA: PARP inhibition → synthetic lethality with BER      │ │
│  │  Germline: MBD4 homozygous (FAVORABLE for PARP)           │ │
│  │                                                            │ │
│  │  Recommendations:                                          │ │
│  │  ✅ Folate 400mcg: Daily (one-carbon metabolism)          │ │
│  │  ✅ B12 1000mcg: Weekly (hematologic support)             │ │
│  │  ✅ Protein 1.2g/kg: Daily (recovery support)             │ │
│  │  ⚠️ Monitor: Anemia, fatigue                              │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
│  Output: NutritionPlan                                           │
│  {                                                               │
│    daily_supplements: [...],                                     │
│    timing_rules: [...],                                         │
│    foods_to_avoid: [...],                                       │
│    foods_to_prioritize: [...],                                  │
│    drug_food_interactions: [...]                                │
│  }                                                               │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

### Phase 7: Unified Care Plan Generation

**Trigger:** All agent outputs ready

```
┌──────────────────────────────────────────────────────────────────┐
│  📋 CARE PLAN ORCHESTRATOR AGENT                                 │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Inputs:                                                         │
│  • PatientProfile                                                │
│  • BiomarkerProfile                                              │
│  • ResistancePrediction                                          │
│  • DrugRanking[]                                                 │
│  • TrialMatches[]                                                │
│  • NutritionPlan                                                 │
│                                                                  │
│  Output: UnifiedCarePlan                                         │
│                                                                  │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  🩺 AYESHA KIANI - UNIFIED CARE PLAN                       │ │
│  │  Generated: December 3, 2025                               │ │
│  │  Confidence: HIGH (all MOATs aligned)                      │ │
│  ├────────────────────────────────────────────────────────────┤ │
│  │                                                            │ │
│  │  📊 MOLECULAR PROFILE                                      │ │
│  │  • MBD4 c.1239delA (homozygous) → BER deficiency          │ │
│  │  • TP53 mutant (IHC) → Checkpoint bypass                  │ │
│  │  • TMB: Pending NGS (expect elevated due to MBD4)         │ │
│  │  • HRD: Inferred from MBD4 (awaiting Myriad score)        │ │
│  │                                                            │ │
│  │  💊 TREATMENT RECOMMENDATIONS                              │ │
│  │  1. NEOADJUVANT: Carboplatin/Paclitaxel (Efficacy: 0.88)  │ │
│  │  2. MAINTENANCE: Olaparib (Efficacy: 0.94) ⭐             │ │
│  │  3. BACKUP: ATR inhibitor trial if resistance             │ │
│  │                                                            │ │
│  │  ⚔️ RESISTANCE MONITORING                                  │ │
│  │  • Baseline risk: 14.5% (no MAPK mutations)               │ │
│  │  • Watch for: MAPK pathway mutations in ctDNA             │ │
│  │  • CA-125 kinetics: Alert if >25% rise                    │ │
│  │                                                            │ │
│  │  🔬 CLINICAL TRIALS                                        │ │
│  │  1. NCT05678901: PARP + ATR (Fit: 0.94) - ENROLLING      │ │
│  │  2. NCT04729387: Olaparib + Cediranib (Fit: 0.88)        │ │
│  │                                                            │ │
│  │  🥗 NUTRITION PLAN                                         │ │
│  │  • During chemo: NAC 600mg post-infusion                  │ │
│  │  • Maintenance: Folate, B12, high protein                 │ │
│  │  • Avoid: Grapefruit (CYP3A4)                            │ │
│  │                                                            │ │
│  │  📅 MONITORING SCHEDULE                                    │ │
│  │  • CA-125: Every 3 weeks during chemo                     │ │
│  │  • CT: After cycle 3, post-surgery, q3 months            │ │
│  │  • ctDNA: Baseline + monthly during maintenance           │ │
│  │                                                            │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

### Phase 8: Continuous Monitoring & Alerts

**Trigger:** Care plan active + new data received

```
┌──────────────────────────────────────────────────────────────────┐
│  🔔 MONITORING & ALERT AGENT                                     │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  Active Monitors:                                                │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  CA-125 KINETICS MONITOR                                   │ │
│  │  • Baseline: Pending                                       │ │
│  │  • Alert threshold: >25% rise from nadir                  │ │
│  │  • Lead time: 3-6 weeks before clinical progression       │ │
│  │  • Status: ⏳ AWAITING BASELINE                            │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  ctDNA MUTATION MONITOR                                    │ │
│  │  • Watch genes: KRAS, NRAS, BRAF, NF1, ABCB1              │ │
│  │  • Alert: New mutation detected                           │ │
│  │  • Action: Flag resistance, suggest alternatives          │ │
│  │  • Status: ⏳ AWAITING BASELINE ctDNA                      │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  TREATMENT RESPONSE MONITOR                                │ │
│  │  • Criteria: RECIST 1.1                                   │ │
│  │  • Alert: PD (progressive disease)                        │ │
│  │  • Action: Trigger resistance analysis, trial re-match    │ │
│  │  • Status: ⏳ AWAITING POST-C3 CT                          │ │
│  └────────────────────────────────────────────────────────────┘ │
│  ┌────────────────────────────────────────────────────────────┐ │
│  │  NEW TRIAL MONITOR                                         │ │
│  │  • Keywords: MBD4, BER deficiency, DDR basket             │ │
│  │  • Alert: New matching trial opens                        │ │
│  │  • Action: Notify oncologist, add to options              │ │
│  │  • Status: ✅ ACTIVE                                       │ │
│  └────────────────────────────────────────────────────────────┘ │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘
```

---

## 🚨 EVENT TRIGGERS & AUTOMATED RESPONSES

### Trigger System Architecture

```
┌─────────────────────────────────────────────────────────────────────────┐
│                         EVENT TRIGGER SYSTEM                             │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                          │
│  ┌─────────────┐    ┌─────────────┐    ┌─────────────┐    ┌──────────┐ │
│  │ DATA INPUT  │───▶│  DETECTOR   │───▶│  EVALUATOR  │───▶│  ACTION  │ │
│  └─────────────┘    └─────────────┘    └─────────────┘    └──────────┘ │
│                                                                          │
│  Data Sources:                                                           │
│  • Lab results (CA-125, CBC, etc.)                                      │
│  • Imaging reports (CT, PET)                                            │
│  • ctDNA results                                                         │
│  • New NGS data                                                          │
│  • Clinical notes                                                        │
│  • ClinicalTrials.gov API                                               │
│                                                                          │
└─────────────────────────────────────────────────────────────────────────┘
```

### Trigger Definitions

```yaml
TRIGGERS:

  # 1. RESISTANCE DETECTED
  resistance_detected:
    condition: "CA-125 > baseline * 1.25 OR MAPK_mutation_in_ctDNA"
    severity: HIGH
    actions:
      - notify_oncologist:
          channel: [email, sms, dashboard]
          message: "Resistance signal detected for {patient_name}"
      - run_resistance_analysis:
          compare_to: baseline
      - suggest_alternatives:
          exclude: current_drug
          prioritize: mechanism_fit
      - re_match_trials:
          keywords: [resistance, salvage, combination]
    escalation:
      if_no_response: 24h
      escalate_to: tumor_board

  # 2. TMB-HIGH DETECTED
  tmb_high_detected:
    condition: "TMB >= 10.0"
    severity: MEDIUM
    actions:
      - update_io_eligibility:
          set: true
      - notify_oncologist:
          message: "Patient now IO-eligible (TMB-H: {tmb} mut/Mb)"
      - re_rank_drugs:
          boost: [pembrolizumab, nivolumab, ipilimumab]
      - match_io_trials:
          keywords: [checkpoint, immunotherapy, TMB-high]

  # 3. MSI-HIGH DETECTED
  msi_high_detected:
    condition: "MSI_status == 'MSI-H' OR dMMR_detected"
    severity: MEDIUM
    actions:
      - update_io_eligibility:
          set: true
      - notify_oncologist:
          message: "MSI-H detected - IO eligible regardless of cancer type"
      - re_rank_drugs:
          boost: [pembrolizumab]
          note: "Pembrolizumab FDA-approved for MSI-H"
      - flag_family:
          reason: "Lynch syndrome screening recommended"

  # 4. HRD SCORE RECEIVED
  hrd_score_received:
    condition: "hrd_score IS NOT NULL"
    severity: LOW
    actions:
      - if: "hrd_score >= 42"
        then:
          - confirm_parp_eligibility:
              confidence: HIGH
          - notify_oncologist:
              message: "HRD+ confirmed (score: {hrd_score}) - PARP eligible"
      - if: "hrd_score < 42"
        then:
          - update_parp_eligibility:
              status: "CONSIDER_ANYWAY"
              reason: "MBD4 BER deficiency is distinct mechanism"
          - notify_oncologist:
              message: "HRD- but MBD4 loss suggests PARP may still work"

  # 5. NEW MATCHING TRIAL
  new_trial_available:
    condition: "trial_match_score >= 0.80 AND trial_status == 'RECRUITING'"
    severity: LOW
    actions:
      - add_to_dashboard:
          section: trials
      - notify_oncologist:
          message: "New trial match: {trial_title} (Fit: {mechanism_fit})"
      - check_eligibility:
          patient: current
          trial: new_trial

  # 6. ADVERSE EVENT REPORTED
  adverse_event_reported:
    condition: "ctcae_grade >= 2"
    severity: HIGH if grade >= 3 else MEDIUM
    actions:
      - log_event:
          grade: ctcae_grade
          type: event_type
      - if: "event_type == 'hematologic'"
        then:
          - suggest_supportive:
              options: [dose_reduction, growth_factors, transfusion]
      - update_nutrition:
          based_on: event_type
      - if: "ctcae_grade >= 3"
        then:
          - escalate_to_oncologist:
              urgent: true

  # 7. TREATMENT RESPONSE
  treatment_response:
    condition: "recist_assessment IS NOT NULL"
    actions:
      - if: "response == 'CR' OR response == 'PR'"
        then:
          - celebrate:
              message: "Good response! Continue current plan."
          - update_plan:
              action: continue
      - if: "response == 'SD'"
        then:
          - monitor_closely:
              increase_frequency: true
      - if: "response == 'PD'"
        then:
          - trigger: resistance_detected
          - recommend_switch:
              to: next_line_therapy
          - re_match_trials:
              keywords: [progressive, refractory, salvage]

  # 8. NGS RESULTS RECEIVED
  ngs_results_received:
    condition: "ngs_report IS NOT NULL"
    severity: HIGH
    actions:
      - parse_mutations:
          source: ngs_report
      - recalculate_all:
          tmb: true
          msi: true
          resistance: true
          drug_ranking: true
      - check_new_mutations:
          compare_to: baseline
      - notify_oncologist:
          message: "NGS results processed. {n_mutations} mutations found."
          include: mutation_summary
```

---

## 🏗️ AGENTIC ARCHITECTURE

### Agent Hierarchy

```
┌──────────────────────────────────────────────────────────────────────────┐
│                      ORCHESTRATOR AGENT (Master)                          │
│  • Coordinates all sub-agents                                             │
│  • Maintains patient state                                                │
│  • Handles inter-agent communication                                      │
│  • Manages event queue                                                    │
└───────────────────────────────┬──────────────────────────────────────────┘
                                │
        ┌───────────────────────┼───────────────────────┐
        │                       │                       │
        ▼                       ▼                       ▼
┌───────────────┐    ┌───────────────┐    ┌───────────────┐
│ DATA AGENTS   │    │ ANALYSIS      │    │ ACTION        │
│               │    │ AGENTS        │    │ AGENTS        │
├───────────────┤    ├───────────────┤    ├───────────────┤
│• Extractor    │    │• Biomarker    │    │• Notification │
│• Parser       │    │• Resistance   │    │• Plan Update  │
│• Validator    │    │• Drug Ranking │    │• Trial Match  │
│• Normalizer   │    │• Trial Match  │    │• Report Gen   │
│               │    │• Nutrition    │    │• Export       │
└───────────────┘    └───────────────┘    └───────────────┘
```

### Agent Communication Protocol

```python
# Agent Message Format
class AgentMessage:
    sender: str           # Agent ID
    recipient: str        # Target agent or "broadcast"
    message_type: str     # "request", "response", "event", "alert"
    payload: dict         # Data
    correlation_id: str   # For request-response matching
    timestamp: datetime
    priority: int         # 1=highest, 5=lowest

# Example: Biomarker Agent → Resistance Agent
AgentMessage(
    sender="biomarker_agent",
    recipient="resistance_agent",
    message_type="event",
    payload={
        "event": "biomarker_calculated",
        "patient_id": "AYE-001",
        "data": {
            "tmb": 3.2,
            "tmb_classification": "TMB-L",
            "hrd_status": "HRD-INFERRED"
        }
    },
    correlation_id="calc-001",
    priority=2
)
```

### State Management

```python
# Central Patient State (maintained by Orchestrator)
class PatientState:
    patient_id: str
    profile: PatientProfile
    biomarkers: BiomarkerProfile
    resistance: ResistancePrediction
    drug_ranking: List[DrugRanking]
    trials: List[TrialMatch]
    nutrition: NutritionPlan
    care_plan: UnifiedCarePlan
    monitoring: MonitoringConfig
    alerts: List[Alert]
    history: List[StateChange]
    last_updated: datetime
    
    def on_change(self, field: str, old_value, new_value):
        """Triggered when any field changes"""
        # Log state change
        self.history.append(StateChange(field, old_value, new_value))
        # Evaluate triggers
        self.evaluate_triggers(field, new_value)
        # Notify relevant agents
        self.broadcast_change(field, new_value)
```

---

## 🖥️ USER INTERFACE INTEGRATION

### Dashboard Layout

```
┌─────────────────────────────────────────────────────────────────────────┐
│  🧬 CrisPRO.ai                              [Ayesha Kiani] [⚙️] [👤]  │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│  ┌─────────────────────────────────────────────────────────────────┐   │
│  │  🔔 ALERTS (2)                                            [▼]   │   │
│  │  • ⚠️ CA-125 baseline still missing - ORDER IMMEDIATELY         │   │
│  │  • ℹ️ New trial match: NCT05678901 (PARP + ATR) - 94% fit       │   │
│  └─────────────────────────────────────────────────────────────────┘   │
│                                                                         │
│  ┌──────────────────────┐  ┌──────────────────────────────────────┐   │
│  │  📊 MOLECULAR        │  │  💊 TREATMENT RECOMMENDATIONS         │   │
│  │  PROFILE             │  │                                      │   │
│  │                      │  │  1. Olaparib (PARP)     [0.94] ⭐    │   │
│  │  MBD4: c.1239delA ⭐ │  │     Tier I | High confidence        │   │
│  │  TP53: Mutant (IHC)  │  │                                      │   │
│  │  TMB: ⏳ Pending     │  │  2. Carboplatin         [0.88]       │   │
│  │  HRD: Inferred       │  │     Tier I | Very high confidence   │   │
│  │  IO: Not eligible    │  │                                      │   │
│  │                      │  │  3. Niraparib (PARP)   [0.91]       │   │
│  │  [View Full Profile] │  │     Tier I | High confidence        │   │
│  └──────────────────────┘  └──────────────────────────────────────┘   │
│                                                                         │
│  ┌──────────────────────┐  ┌──────────────────────────────────────┐   │
│  │  ⚔️ RESISTANCE       │  │  🔬 CLINICAL TRIALS                  │   │
│  │                      │  │                                      │   │
│  │  Platinum: HIGH      │  │  NCT05678901                        │   │
│  │  sensitivity         │  │  PARP + ATR in DDR-Deficient OC     │   │
│  │                      │  │  Mechanism Fit: 94% ⭐               │   │
│  │  Risk: 14.5%         │  │  Status: RECRUITING                 │   │
│  │  (baseline)          │  │  [View Details] [Check Eligibility] │   │
│  │                      │  │                                      │   │
│  │  MAPK: Wild-type ✅  │  │  NCT04729387                        │   │
│  │  NF1: Not detected   │  │  Olaparib + Cediranib               │   │
│  │                      │  │  Mechanism Fit: 88%                 │   │
│  │  [View Full Analysis]│  │  [View All 5 Matches]               │   │
│  └──────────────────────┘  └──────────────────────────────────────┘   │
│                                                                         │
│  ┌──────────────────────────────────────────────────────────────────┐  │
│  │  🥗 NUTRITION PLAN                           📅 MONITORING       │  │
│  │                                                                  │  │
│  │  During Carboplatin:                         Next Steps:         │  │
│  │  • NAC 600mg post-infusion                  ☐ CA-125 baseline   │  │
│  │  • Vitamin D 2000 IU daily                  ☐ NGS results       │  │
│  │  • Avoid grapefruit                         ☐ HRD score         │  │
│  │                                              ☐ CT post-C3        │  │
│  │  [View Full Plan]                           [View Schedule]      │  │
│  └──────────────────────────────────────────────────────────────────┘  │
│                                                                         │
│  ┌──────────────────────────────────────────────────────────────────┐  │
│  │  💬 CoPilot                                              [Chat]  │  │
│  │  "Ask me anything about Ayesha's case..."                        │  │
│  │  ┌────────────────────────────────────────────────────────────┐  │  │
│  │  │ Quick: [Why PARP?] [Resistance risk?] [Trial eligibility?] │  │  │
│  │  └────────────────────────────────────────────────────────────┘  │  │
│  └──────────────────────────────────────────────────────────────────┘  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

---

## 📡 API ENDPOINTS

### Master Orchestration Endpoint

```yaml
POST /api/orchestrate/full
Description: Initiates full end-to-end pipeline
Input:
  patient_data: File | PatientProfile
  options:
    run_all: boolean
    async: boolean
Output:
  job_id: string
  status: "started"
  estimated_time: "45 seconds"
  webhook_url: string (for completion notification)
```

### Individual Agent Endpoints

```yaml
# Data Extraction
POST /api/agents/extract
Input: { file: File, file_type: string }
Output: { patient_profile: PatientProfile, quality_flags: string[] }

# Biomarker Calculation
POST /api/agents/biomarkers
Input: { mutations: Mutation[], options: BiomarkerOptions }
Output: { biomarker_profile: BiomarkerProfile }

# Resistance Prediction
POST /api/agents/resistance
Input: { mutations: Mutation[], current_treatment: string }
Output: { resistance_prediction: ResistancePrediction }

# Drug Ranking
POST /api/agents/drugs
Input: { patient_profile: PatientProfile, biomarkers: BiomarkerProfile }
Output: { drug_ranking: DrugRanking[] }

# Trial Matching
POST /api/agents/trials
Input: { mechanism_vector: float[7], disease: string }
Output: { trial_matches: TrialMatch[] }

# Nutrition
POST /api/agents/nutrition
Input: { drugs: string[], germline: GermlineProfile }
Output: { nutrition_plan: NutritionPlan }

# Care Plan Generation
POST /api/agents/care-plan
Input: { all_agent_outputs: AgentOutputs }
Output: { unified_care_plan: UnifiedCarePlan }

# Event Trigger
POST /api/events/trigger
Input: { event_type: string, data: any }
Output: { actions_taken: Action[], alerts_sent: Alert[] }
```

---

## 🔐 SECURITY & COMPLIANCE

### Data Flow Security

```
┌─────────────────────────────────────────────────────────────────────────┐
│  SECURITY LAYERS                                                         │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                          │
│  Layer 1: Transport                                                      │
│  • TLS 1.3 for all API calls                                            │
│  • Certificate pinning                                                   │
│                                                                          │
│  Layer 2: Authentication                                                 │
│  • OAuth 2.0 / JWT tokens                                               │
│  • Multi-factor authentication                                           │
│  • Role-based access control (RBAC)                                     │
│                                                                          │
│  Layer 3: Data Encryption                                               │
│  • AES-256 encryption at rest                                           │
│  • Field-level encryption for PII                                       │
│  • Key rotation every 90 days                                           │
│                                                                          │
│  Layer 4: Audit                                                          │
│  • Complete audit trail of all actions                                  │
│  • Immutable logs (append-only)                                         │
│  • HIPAA-compliant data retention                                       │
│                                                                          │
│  Layer 5: Compliance                                                     │
│  • HIPAA / HITECH compliance                                            │
│  • SOC 2 Type II certification                                          │
│  • GDPR-ready (data portability, right to delete)                       │
│                                                                          │
└─────────────────────────────────────────────────────────────────────────┘
```

---

## 📈 SUCCESS METRICS

### Product KPIs

| Metric | Target | Measurement |
|--------|--------|-------------|
| **Time to First Insight** | <60 seconds | Upload → Care plan generated |
| **Alert Lead Time** | 3-6 weeks | Resistance alert before clinical PD |
| **Trial Match Accuracy** | >90% | Mechanism fit correlation with enrollment |
| **User Engagement** | >80% DAU | Daily active oncologists |
| **Alert Action Rate** | >70% | Alerts that result in clinical action |

### Clinical KPIs

| Metric | Target | Measurement |
|--------|--------|-------------|
| **Time to Treatment** | -20% | Days from diagnosis to first treatment |
| **Trial Enrollment** | +30% | Patients enrolled in matching trials |
| **Resistance Detection** | -4 weeks | Time to detect vs standard monitoring |
| **Treatment Response** | +15% | Response rate with optimized selection |

---

## 🗓️ IMPLEMENTATION ROADMAP

### Phase 1: Core Pipeline (Weeks 1-2)
- [ ] Data extraction agent (PDF, VCF, MAF parsing)
- [ ] Biomarker calculation agent (TMB, MSI, HRD)
- [ ] Resistance prediction agent (MAPK, DDR)
- [ ] Basic orchestrator

### Phase 2: Intelligence Layer (Weeks 3-4)
- [ ] Drug ranking agent (S/P/E framework)
- [ ] Trial matching agent (mechanism vector)
- [ ] Nutrition agent (drug-food interactions)
- [ ] Care plan generator

### Phase 3: Monitoring & Triggers (Weeks 5-6)
- [ ] Event trigger system
- [ ] Alert routing
- [ ] CA-125 kinetics monitor
- [ ] ctDNA mutation monitor

### Phase 4: UI Integration (Weeks 7-8)
- [ ] Dashboard components
- [ ] CoPilot integration
- [ ] Mobile notifications
- [ ] Report export

### Phase 5: Hardening (Weeks 9-10)
- [ ] Security audit
- [ ] Performance optimization
- [ ] Load testing
- [ ] Documentation

---

## 🎯 THE ULTIMATE MOAT

### What No Competitor Has:

| Capability | Us | Competitors |
|------------|-----|-------------|
| **End-to-end orchestration** | ✅ Upload → Care plan → Monitoring | ❌ Fragmented tools |
| **Agentic intelligence** | ✅ Autonomous agents, triggers, alerts | ❌ Manual workflows |
| **Validated biomarkers** | ✅ TMB r=0.933, MAPK RR=1.97 | ❌ Unvalidated or black-box |
| **Mechanism-based matching** | ✅ 7D vector, mechanism fit | ❌ Keyword matching only |
| **Toxicity-nutrition integration** | ✅ Drug MoA → Food recommendations | ❌ Generic advice |
| **Continuous monitoring** | ✅ Real-time triggers, early alerts | ❌ Point-in-time analysis |
| **Transparent reasoning** | ✅ Full provenance, auditable | ❌ Black-box AI |

### The Defensible Position:

```
┌─────────────────────────────────────────────────────────────────────────┐
│                                                                         │
│  🏆 THE CRISPRO.AI MOAT                                                 │
│                                                                         │
│  Layer 1: VALIDATED SCIENCE                                             │
│  • TMB validated against 1,895 TCGA samples (r=0.933)                  │
│  • Resistance validated on 469 TCGA-OV patients (RR=1.97)              │
│  • S/P/E framework with real Evo2 integration                          │
│                                                                         │
│  Layer 2: INTEGRATED WORKFLOW                                           │
│  • Single upload → Full intelligence                                    │
│  • All MOATs working together, not siloed                              │
│  • Unified care plan, not fragmented reports                           │
│                                                                         │
│  Layer 3: AGENTIC INTELLIGENCE                                          │
│  • Autonomous agents that don't sleep                                   │
│  • Event triggers that catch signals early                             │
│  • Continuous monitoring, not point-in-time                            │
│                                                                         │
│  Layer 4: CLINICAL INTEGRATION                                          │
│  • CoPilot for real-time assistance                                    │
│  • Dashboard for at-a-glance status                                    │
│  • Alerts that drive action                                            │
│                                                                         │
│  ═══════════════════════════════════════════════════════════════════   │
│  RESULT: Precision oncology that works while you sleep.                 │
│  ═══════════════════════════════════════════════════════════════════   │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
```

---

**Document Status:** ✅ MASTER BLUEPRINT COMPLETE  
**Owner:** CrisPRO.ai Product Team  
**Next Review:** Weekly during implementation

---

**"Upload once. Track forever. Never miss a signal."** 🧬🚀
